Xlife Sciences AG / Key word(s): MiscellaneousPortfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CESTLysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Scienc.
Xlife Sciences AG / Key word(s): Miscellaneousalytas therapeutics collaborates with spin-off from the German Diabetes Center 28.11.2022 / 07:00 CET/CESTXlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of.
Xlife Sciences AG / Key word(s): Miscellaneous21-Nov-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator ba.
Xlife Sciences AG / Key word(s): Half Year Results28-Sep-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. B.
Xlife Sciences AG / Key word(s): Annual Results29-Apr-2022 / 23:38 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Highlights 2021: Successful exit of a project company through the initial public offering of Vitruvia Medical on th.